Latest Transaction Adds Chemotherapy Management Software and
                   Expands the Company in Europe

LENEXA, Kan., April 18, 2012 (GLOBE NEWSWIRE) -- Mediware(R)
Information Systems, Inc. (Nasdaq:MEDW) announced that it has finalized
the acquisition of the Cyto Management System (CMS) from Cobbler ICT
Services BV for EURO1.7 million ($2.2 million USD). The CMS software,
which is currently deployed in Holland and Belgium, provides healthcare
organizations a comprehensive chemotherapy management solution to track
patients, manage highly individualized medication-based treatment
plans, help control costs, and report outcomes associated with cancer
therapies.

Mediware has been analyzing chemotherapy and cancer management
solutions for more than 18 months. By acquiring a proven solution and
focusing on healthcare needs that are adjacent to Mediware's existing
pharmacy expertise, Mediware believes it will be able to leverage its
core capabilities and strong customer relationships to expand adoption
of the CMS software in Europe and throughout the UK.

Mediware plans to continue its existing distribution agreements in the
Netherlands and Belgium and has formalized a European sales and support
center in Eindhoven, Netherlands. The company will also make the
software available to the UK and Irish markets where Mediware's
UK-based JAC medication management product suite is used by more than
50 percent of UK hospitals. Additional geographic expansion will be
considered as opportunities arise.

About Mediware

Mediware delivers interoperable best-of-breed software systems that
improve efficiencies and address safety concerns, enabling healthcare
organizations to improve care processes while decreasing costs. Core
Mediware solutions include blood management technologies for hospitals
and blood centers; medication management solutions for hospitals,
behavioral health facilities, infusion and specialty pharmacy
providers; and business intelligence-based performance management
solutions for clinical, regulatory and financial aspects of the broader
healthcare market. For more information about Mediware products and
services, visit our website at www.mediware.com.

The Mediware Information Systems, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5249

About JAC

JAC is the UK's leading medicine management systems specialist, with
the largest installed base of Electronic Prescribing and Medicines
Administration systems in UK hospitals. With over 20 years experience
within medicines management, JAC provides pharmacy stock control,
e-prescribing and medicines administration as a single integrated
solution along with associated services and third-party interfaces.
JAC's systems are used in more than half of all NHS trusts in England
as well as sites in Scotland, Wales, Northern Ireland, Ireland and
South Africa.

About the Cyto Management System The CMS software is a comprehensive
'closed loop' solution for managing chemotherapy treatments that is
focused on reducing errors, streamlining patient management and
optimizing efficiency through the care treatment process. Consisting of
five main components, CMS manages the prescription of chemotherapy for
the physician, the planning of the chemotherapy for the patient, the
planning for the preparation of the chemo therapy, the preparation of
cytotoxic drugs and all the other sterile preparations. CMS is designed
to be highly interoperable and includes multi-lingual capabilities to
allow the software to be easily configured for international
distribution.

Certain statements in this press release may constitute
"forward-looking" statements within the meaning of the Private
Securities Litigation Reform Act of 1995, as the same may be amended
from time to time (the "Act") and are intended to be covered by the
safe harbor created thereby. Such forward-looking statements are not
necessarily based on historical facts and involve known and unknown
risks, uncertainties and other factors which may cause the actual
results of the Company to be materially different from any future
results expressed or implied by such forward looking statements. These
risk and uncertainties include but are not limited to those disclosed
in the Company's Annual Reports on Form 10-K, Quarterly Reports on Form
10-Q and Current Reports on Form 8-K. The Company does not intend to,
and undertakes no obligation to, update forward-looking statements to
reflect changed assumptions, the occurrence of unanticipated events or
changes in future operating results, financial condition or business
over time. The Company regularly posts important information to the
investor relations section of its website


CONTACT: John Van Blaricum
         913-307-1017